Study of ORIC-101 in Combination With Enzalutamide

Clinical trial NCT04033328 · TERMINATED

Trial details

NCT number: NCT04033328
Sponsor: ORIC Pharmaceuticals
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Prostatic Neoplasms

Start date: 2019-10-28
Primary completion: 2022-11-22
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.